Bristol-Myers Squibb (BMY) to Release Earnings on Thursday

Bristol-Myers Squibb (NYSE:BMY) is scheduled to release its earnings data before the market opens on Thursday, April 25th. Analysts expect Bristol-Myers Squibb to post earnings of ($4.51) per share for the quarter. Bristol-Myers Squibb has set its FY 2024 guidance at 7.100-7.400 EPS and its FY24 guidance at $7.10-7.40 EPS.Parties interested in registering for the company’s conference call can do so using this link.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. The firm had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The business’s revenue for the quarter was up .6% on a year-over-year basis. During the same period in the previous year, the business earned $1.82 EPS. On average, analysts expect Bristol-Myers Squibb to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Bristol-Myers Squibb Price Performance

NYSE:BMY opened at $49.14 on Tuesday. Bristol-Myers Squibb has a 52-week low of $47.58 and a 52-week high of $70.93. The stock has a fifty day moving average of $51.22 and a 200 day moving average of $51.38. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. The firm has a market capitalization of $99.59 billion, a price-to-earnings ratio of 12.73, a P/E/G ratio of 1.48 and a beta of 0.39.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.88%. Bristol-Myers Squibb’s payout ratio is currently 62.18%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BMY. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Finally, Bank of America cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $61.18.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.